Award recordCONTRACT

ACORDA THERAPEUTICS, INC.

PIID VA25914F1892· VHA· 259-NETWORK CONTRACT OFFICE 19· 6505 · DRUGS AND BIOLOGICALS· FY2014· $114,861 net obligations· UEI R5D3FUPFFPK4· NY

Description

EXPRESS REPORT - 1 PHARMACY ORDERS DALFAMPRIDINE (AMPYRA) 10MG PURCHASE ORDERS REPORTED: 554A40199

Base award description: EXPRESS REPORT - 1 PHARMACY ORDERS DALFAMPRIDINE (AMPYRA) 10MG PURCHASE ORDERS REPORTED: 554A40027

First action · last action
2013-10-21 · 2014-02-07
Transactions
2
First transaction's obligation
$58,337
Base + all options value (sum of deltas)
$114,861
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
Parent IDV
V797P5233B
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING

Modification chain · 2 transactions

Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.

$114,861$0Base award · 2013-10-21 · this action $58,337 · running total $58,337Modification P00001 · 2014-02-07 · this action $56,525 · running total $114,861
  • Base2013-10-21+$58,337= $58,337
  • Mod P000012014-02-07+$56,525= $114,861
TransactionAction dateThis action (delta)Running totalDescription on this transaction
Base2013-10-21+$58,337$58,337EXPRESS REPORT - 1 PHARMACY ORDERS DALFAMPRIDINE (AMPYRA) 10MG PURCHASE ORDERS REPORTED: 554A40027
Mod P00001· FUNDING ONLY ACTION2014-02-07+$56,525$114,861EXPRESS REPORT - 1 PHARMACY ORDERS DALFAMPRIDINE (AMPYRA) 10MG PURCHASE ORDERS REPORTED: 554A40199

Related awards · 11

Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.

Other VA awards to the same recipient (UEI R5D3FUPFFPK4)

AwardOffice · PSC / listingNet obligationsFY
36C77024N0067NATIONAL CMOP OFFICE (36C770) · 6505 · DRUGS AND BIOLOGICALS$493,607FY2024
36E79724A0005NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2024
36C77024N0027NATIONAL CMOP OFFICE (36C770) · 6505 · DRUGS AND BIOLOGICALS$444,505FY2024
36F79723D0194NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS$0FY2023
36E79723A0011NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2023
36C77023N0057NATIONAL CMOP OFFICE (36C770) · 6505 · DRUGS AND BIOLOGICALS$529,877FY2023

Other recipients under 6505 from 259-NETWORK CONTRACT OFFICE 19 (most recent first)

AwardRecipientOfficeNet obligationsFY
VA25916E2832GRIFOLS USA LLC259-NETWORK CONTRACT OFFICE 19$16,949FY2016
VA25916P2108BAXALTA US INC.259-NETWORK CONTRACT OFFICE 19$6,212FY2016
VA25916E2677GRIFOLS THERAPEUTICS LLC259-NETWORK CONTRACT OFFICE 19$12,066FY2016
VA25916P1705MCKESSON CORPORATION259-NETWORK CONTRACT OFFICE 19$11,043FY2016
VA25916E2674CAREMARK RX, L.L.C.259-NETWORK CONTRACT OFFICE 19$17,262FY2016

Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA25914F1892_3600_V797P5233B_3600 · retrieved 2026-09-26.